Rivoli Group announces completion of its new international corporate strategy
Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/
Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire)
The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together.
"This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said.
The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings and to redefine business processes.
In addition to the integration of newly developed risk management solutions, the coverage presence in the emerging markets with above-average growth potential, as well as the maximum achievable flexibility and scope of the company's investment products play an essential role.
Also, the necessary infrastructure is to be created in an agreement between all involved parties to increase the growth in the Venture Capital division exponentially.
The management of the Rivoli Group expects to implement the necessary measures during the fourth quarter of this business year.
The renewal of the communication infrastructure (website, corporate identity, etc.) is one of the numerous measures to increase the range, which initiates in combination with the other necessary steps.
About Rivoli Group AG
The Rivoli Group is an international consulting and investment company headquartered in Zurich. In addition to financing innovative-oriented companies, from the seed and early-stage phases, the Swiss Group has specialized in project development and financing in developing countries with above-average growth opportunities. The company currently manages a cumulative project volume of approximately CHF 7 billion (approximately EUR 6 billion).
Currently, the company is reorienting its corporate strategy. Further information on the reorientation will be announced shortly as part of a management letter on the company's website www.rivoli-group.com.
Rivoli Group AG
Sarah Mertens, +41 44 388 5459
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 10:18:00 CEST | Pressemelding
The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 10:00:00 CEST | Pressemelding
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc
Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.024.4.2019 09:00:00 CEST | Pressemelding
Fiorano Software, a leader in Integration Middleware, API Management and peer-to-peer distributed systems, announced today the release of version 12.0 of the Fiorano ESB and API Management platform. The latest release with new adapters and tools includes enhanced and optimised features to improve performance of its servers delivering a more productive SOA and API Management deployment with a significant incremental return on investment. The platform offers a unified profile to run all Fiorano Servers in a single process and ships with several new adapters including a Kafka Connector, DynamoDB, AS4Connector, SMPPSend and WebSockets. Users can now import Event Processes directly from the Dashboard and optimize CRC processes by fetching components from local repositories. The new platform provides a new HTML5 dashboard, monetisation and security policies like JWT/JWS for API Management while supporting Open API specifications, OpenId Connect and time-based accessing and quota policies alo
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 08:30:00 CEST | Pressemelding
Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 08:30:00 CEST | Pressemelding
Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 08:15:00 CEST | Pressemelding
Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary